27 Results for "

HDAC5

" in MedChemExpress (MCE) Product Catalog:
Products (27)

27 Results for "HDAC5" in MCE Product Catalog:

  • Isoforms Recommended:
  • Targets Recommended:
31
31 Publications Verification
Cat. No.: HY-18998
CAS No.: 1418033-25-6
Target:  

HDAC

Research Areas:  

Cancer

LMK-235 is a potent and selective HDAC4/5 inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC50s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-12164
CAS No.: 726169-73-9
Purity:  99.13%
Synonyms: MGCD0103
Target:  

HDAC Autophagy Apoptosis

Research Areas:  

Cancer

Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC50s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.
loading...
    loading...
21
21 Cited Publications
Cat. No.: HY-18360
CAS No.: 1314890-29-3
Target:  

HDAC

Research Areas:  

Cancer

TMP269 is a novel and selective class IIa histone deacetylase (HDAC) inhibitor with IC50s of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-18361
CAS No.: 1314891-22-9
Target:  

HDAC

Research Areas:  

Cancer

TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor with Kis of 59, 60, 26, 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-112719
CAS No.: 315698-07-8
Purity:  99.66%
Target:  

HDAC

Research Areas:  

Cancer

BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-13432
CAS No.: 1256448-47-1
Purity:  99.34%
Synonyms: CHR-3996
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

Nanatinostat (CHR-3996) is a potent, class I selective and orally active HDAC inhibitor with IC50s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat has low activity against HDAC5 (IC50 of 200 nM) and HDAC6 (IC50 of 2100 nM). Nanatinostat induces apoptosis in myeloma cells. Nanatinostat has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119939
CAS No.: 1629729-98-1
Purity:  98.10%
Synonyms: CHDI00390576
Target:  

HDAC

Research Areas:  

Cancer

CHDI-390576, a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor with IC50s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-143248
CAS No.: 2770300-35-9
Purity:  99.48%
KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-152226
CAS No.: 2284460-01-9
Purity:  98.71%
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

MC2590 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2590 is a inhibitor of HDAC1-3, -6, -8, and -10 (class I/IIb-selective inhibitor) with IC50s of 0.015 μM-0.156 μM. MC2590 also inhibits HDAC isoforms HDAC4, HDAC5, HDAC7, HDAC9, HDAC11 with IC50s of 1.35 μM-3.98 μM. MC2625 induces G2/M cell cycle arrest and modulates pro- and anti-apoptotic microRNAs towards apoptosis induction .
loading...
    loading...
Cat. No.: HY-148624
CAS No.: 3025894-92-9
Target:  

HDAC

Research Areas:  

Neurological Disease

CHDI-00484077 (Compound 12) is a CNS-penetrant class IIa HDAC inhibitor, with IC50s of 0.01 μM (HDAC4), 0.02 μM(HDAC5), 0.02 μM (HDAC7), 0.03 μM (HDAC9) respectively. CHDI-00484077 can be used for research of huntington’s disease .
loading...
    loading...
Cat. No.: HY-RS06076
Research Areas:  

Others

HDAC5 Human Pre-designed siRNA Set A contains three designed siRNAs for HDAC5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS06077
Research Areas:  

Others

Hdac5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hdac5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS06078
Research Areas:  

Others

Hdac5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hdac5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P10462
CAS No.: 1403753-45-6
Synonyms: Synthetic anti-inflammatory peptide 15
Target:  

HDAC NF-κB

Research Areas:  

Inflammation/Immunology

SAP15 (Synthetic anti-inflammatory peptide 15) is a synthetic anti-inflammatory peptide consisting of 15 amino acids designed from human beta-defensin 3. SAP15 has the ability to penetrate cells and is able to induce downregulation of intracellular inflammation. SAP15 inhibits inflammation by inhibiting the phosphorylation of HDAC5 and thereby reducing the phosphorylation of NF-κB p65. SAP15 inhibits HDAC5 and NF-κB p65 phosphorylation in LPS (HY-D1056)-induced macrophages. SAP15 increases the expression of aggrecan and type II collagen and decreases the expression of osteocalcin in LPS-induced chondrocytes. SAP15 can be used in the study of inflammation regulation and anti-inflammatory therapy of biomaterials .
loading...
    loading...
Cat. No.: HY-114548
CAS No.: 104473-83-8
Purity:  ≥98.0%
Target:  

Guanylate Cyclase

Research Areas:  

Infection

Ebselen oxide, the selenone analogue of Ebselen, covalently modifies diguanylate cyclase (DGC) to inhibit c-di-GMP-receptor interactions and reduces DGC activity. Ebselen oxide also inhibits alginate production (IC50=14 μM) by Pseudomonas aeruginosa. Ebselen oxide inhibits HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9 (IC50 ranging from 0.2 to 4.7 μM) .
loading...
    loading...
Cat. No.: HY-P10462A
Synonyms: Synthetic anti-inflammatory peptide 15 acetate
Target:  

HDAC NF-κB

Research Areas:  

Inflammation/Immunology

SAP15 (Synthetic anti-inflammatory peptide 15) acetate is a synthetic anti-inflammatory peptide consisting of 15 amino acids designed from human beta-defensin 3. SAP15 acetate has the ability to penetrate cells and is able to induce downregulation of intracellular inflammation. SAP15 acetate inhibits inflammation by inhibiting the phosphorylation of HDAC5 and thereby reducing the phosphorylation of NF-κB p65. SAP15 acetate inhibits HDAC5 and NF-κB p65 phosphorylation in LPS (HY-D1056)-induced macrophages. SAP15 acetate increases the expression of aggrecan and type II collagen and decreases the expression of osteocalcin in LPS-induced chondrocytes. SAP15 acetate can be used in the study of inflammation regulation and anti-inflammatory therapy of biomaterials .
loading...
    loading...
Cat. No.: HY-169940
Target:  

HDAC

Research Areas:  

Inflammation/Immunology

Fibrostat (Compound 5n) is a selective HDAC6 inhibitor that exerts antifibrotic effects by inhibiting HDAC6 activity, with an IC50 value of 63 nM. It also exhibits good selectivity over HDAC1, HDAC3, HDAC5, HDAC8, HDAC10, and HDAC11. Fibrostat significantly downregulates fibrotic markers (fibronectin and collagen 1) in fibroblasts. Additionally, Fibrostat demonstrated no toxicity in rat-perfused heart and zebrafish larvae models. Fibrostat shows potential for research into fibrosis-related diseases .
loading...
    loading...
Cat. No.: HY-112719B
CAS No.: 2444837-63-0
Target:  

HDAC

Research Areas:  

Cancer

BRD 4354 (ditrifluoroacetate) is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively .
loading...
    loading...
Cat. No.: HY-12164R
CAS No.: 726169-73-9
Synonyms: MGCD0103 (Standard)
Research Areas:  

Cancer

Mocetinostat (Standard) is the analytical standard of Mocetinostat. This product is intended for research and analytical applications. Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC50s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.
loading...
    loading...
Cat. No.: HY-13432A
CAS No.: 1256448-48-2
Synonyms: CHR-3996 TFA
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

Nanatinostat (CHR-3996) TFA is a potent, class I selective and orally active HDAC inhibitor with IC50s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat TFA has low activity against HDAC5 (IC50 of 200 nM) and HDAC6 (IC50 of 2100 nM). Nanatinostat TFA induces apoptosis in myeloma cells. Nanatinostat TFA has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .
loading...
    loading...